Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics
News Dec 18, 2014
Baxter International Inc. has announced that it has entered into a definitive agreement to sell its proprietary Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics, Inc. Financial details were not disclosed.
The Vero cell platform is an advanced, cell-based technology for vaccines production. The agreement with Nanotherapeutics includes all assets related to the platform, including vaccines for H5N1, H1N1 and seasonal influenza. The agreement also includes investigational vaccine programs for Ross River virus, Chikungunya disease and West Nile virus.
In recent weeks, the company has also completed the sale of its commercial vaccines business and related manufacturing facilities to Pfizer Inc.
"The divestiture of the vaccines franchise will allow Baxter BioScience to enhance focus in core therapeutic areas of hematology, oncology and immunology, as it prepares to become an independent biopharmaceutical company," said Ludwig Hantson, Ph.D., president of Baxter BioScience. "In addition, these transactions provide flexibility to direct resources toward strategic priorities that will drive future growth."
Baxter's financial results for 2014 reflect the operating results from its vaccines franchise as discontinued operations.
Adaptive Designs in Clinical Trials conference 2019
Apr 01 - Apr 02, 2019
Pre-Filled Syringes & Injectable Drug Devices Europe
Jan 16 - Jan 17, 2019
3rd International Conference and Exhibition on Nanomedicine and Drug Delivery
Mar 13 - Mar 14, 2019
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019